GlaxoSmithKline

GSK reports positive interim Phase II trial results for its mRNA-based multivalent influenza vaccine candidate, GSK4382276A, meeting pre-defined success criteria in both younger and older adult groups. The vaccine, encoding antigens matched to WHO-recommended influenza strains, showed potential for improved immune responses compared to current vaccines, prompting GSK to advance the programme into late-stage clinical development.

GSK granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma, based on DREAMM-7 trial results.

Moderna delays break-even goal to 2028, expects 2025 sales below 2024 forecast, and plans to cut $1.1 billion in R&D costs from 2026. The company cites challenges in launching new products and slower-than-expected RSV vaccine adoption.

Fulcrum Therapeutics' experimental drug losmapimod failed a Phase 3 trial for muscular dystrophy FSHD, leading to suspension of its development. Despite positive signs in previous tests, losmapimod missed its main objective and secondary goals. Fulcrum's shares dropped 60%, and the company will focus on its sickle cell disease treatment, expecting Phase 1 data next year. The FDA previously suspended testing of the sickle cell therapy for six months.

Biomarkers, the unique genetic signature of tumors, help oncologists match patients with the most effective treatment options, transforming cancer care across various tumor types.

GSK announced positive phase II trial data for its mRNA seasonal flu vaccine, meeting success criteria in younger and older participants. The vaccine showed acceptable safety and reactogenicity. GSK plans to advance to late-stage clinical development. Stock is down 1.52% at $43.10.

GSK’s mRNA flu vaccine succeeds against both strains in Phase 2.

GSK's phase 2 data for its seasonal influenza mRNA vaccine, GSK4382276A, showed robust immune responses against A and B strains in older and younger adults, supporting progression to phase 3 trials. The vaccine demonstrated acceptable safety and reactogenicity profiles, aiming to develop a best-in-class vaccine for greater protection during flu season.

GSK's mRNA-based seasonal flu vaccine successfully completed phase II trials, showing positive immune responses and safety profiles, advancing to phase III. The company's full control over development and manufacturing from CureVac, along with AI/ML-based optimizations, strengthens its mRNA vaccine program. GSK's financial stability, with a market cap of $88.32B and a dividend yield of 3.46%, supports ongoing vaccine technology investments.